Lurbinectedin is a synthetic inhibitor of RNA polymerase II, which has shown potential in cancer treatment, particularly in the management of small cell lung cancer (SCLC) [1]. Research on lurbinectedin has primarily focused on its efficacy as a monotherapy or in combination with other chemotherapeutic agents [1][2]. However, there is ongoing interest in exploring lurbinectedin's potential in combination with immunotherapies, which work by boosting the body's immune system to fight cancer.
According to the clinical trials database on drugpatentwatch.com, there are ongoing clinical trials investigating the use of lurbinectedin in combination with immune checkpoint inhibitors, such as atezolizumab and pembrolizumab, in patients with advanced SCLC and non-small cell lung cancer (NSCLC) [3]. These trials aim to evaluate the safety and efficacy of lurbinectedin when combined with immunotherapies, with the primary endpoints being overall response rate (ORR) and progression-free survival (PFS).
Some examples of clinical trials using lurbinectedin in immunotherapy include:
* A phase 1b trial (NCT04169125) evaluating the efficacy and safety of lurbinectedin in combination with atezolizumab in patients with advanced SCLC [3].
* A phase 2 trial (NCT03778672) investigating the efficacy of lurbinectedin in combination with pembrolizumab in patients with locally advanced or metastatic NSCLC.
* A phase 1/2 trial (NCT03007169) evaluating the safety and efficacy of lurbinectedin in combination with nivolumab in patients with advanced NSCLC.
While these clinical trials are ongoing, the results are not yet available, and it is premature to draw any conclusions about the effectiveness of lurbinectedin in combination with immunotherapies.
Sources:
[1] https://www.drugpatentwatch.com/drug/1331
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331332/
[3] https://clinicaltrials.gov/
Sources cited:
1. https://www.drugpatentwatch.com/drug/1331
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331332/
3. https://clinicaltrials.gov/